Cycloserine/lurasidone
Combination of | |
---|---|
Cycloserine | NMDA receptor modulator |
Lurasidone | Atypical antipsychotic |
Clinical data | |
Routes of administration | Oral |
ATC code | None |
Legal status | |
Legal status | |
Identifiers | |
Synonyms | Cyclurad |
Cycloserine/lurasidone (proposed brand name Cyclurad) is a combination formulation of cycloserine (D-cycloserine), a partial agonist of the glycine site of the NMDA receptor, and lurasidone, an atypical antipsychotic, which is under development for the treatment of bipolar depression by NeuroRx.[1]
References
- ↑ Kantrowitz, Joshua T.; Halberstam, Batsheva; Gangwisch, James (2015). "Single-Dose Ketamine Followed by Daily d-Cycloserine in Treatment-Resistant Bipolar Depression". The Journal of Clinical Psychiatry: 737–738. doi:10.4088/JCP.14l09527. ISSN 0160-6689.
External links
This article is issued from Wikipedia - version of the 7/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.